Program
Corporate Symposium
Corporate Symposium
By Novo Nordisk

Chairperson: TBD
Thursday 3 September

09:00-10:00

TBDTBDTBD


Corporate Symposium
By Alvogen

Chairperson: TBD
Thursday 3 September

10:00-11:00

TBDTBDTBD


Corporate Symposium
By MSD

Chairperson: TBD
Thursday 3 September

11:00-12:00

TBDTBDTBD


Corporate Symposium
By Hanmi, Gwangdong, Inno.N

Chairperson: TBD
Thursday 3 September

13:30-15:00

TBDTBDTBD


Corporate Symposium (K)
By JW Pharmaceutical, Dong-A ST

Chairperson: TBD
Thursday 3 September

19:00-19:30

All statins are the same in safety and outcome for Asian Sang Yong KIMDivision of Endocrinology and Metabolism, Chosun University, Korea
19:30-20:00

New paradigm of glycemic variability: EVERGREEN studyIn-Kyung JEONGDepartment of Endocrinology and Metabolism, Kyung Hee University, Korea


Corporate Symposium
By Sanofi-Aventis

Chairperson: TBD
Friday 4 September

07:30-08:00

Challenging the injectable treatment paradigm in T2DM: Rationale for fixed-ratio co-formulation Su-Jin JEONG Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong General Hospital


Corporate Symposium
By LG Chem

Chairperson: TBD
Friday 4 September

07:30-08:00

Solution for optimal glycemic control in early and advanced stages of type 2 diabetes Tae Jung OH Seoul National University, Korea


Corporate Symposium
By Olympus

Chairperson: Seung Wan RYU (Keimyung University, Korea)
Friday 4 September

07:30-08:00

Bariatric surgery using 3D scope Han Hong LEE The Catholic University of Korea, Korea


Corporate Symposium
By MSD

Chairperson: TBD
Friday 4 September

12:40-13:10

The latest option for the treatment of type 2 diabetes Hye Jin YOO Department of Endocrinology and Metabolism, Korea University, Korea


Corporate Symposium
By Alvogen

Chairperson: TBD
Friday 4 September

12:40-13:10

Observed improvements of comorbid conditions in obese patients utilizing combination phentermine plus topiramate extended release Santosh T. VARGHESE VIVUS Inc., USA


Corporate Symposium
By Medtronic

Chairperson: Soo Min AHN (Hallym University, Korea)
Friday 4 September

12:40-13:10

Bariatric training and education program in Australia Lilian KOW Adelaide Bariatric Centre, Australia


Corporate Symposium
By Daewoong Pharmaceutical

Chairperson: TBD
Friday 4 September

12:40-13:10

Clinical application of a new convenient continuous glucose monitoring device: FreeStyle Libre짰 Soo LIM Department of Internal Medicine, Seoul National University Bundang Hospital, Korea


Corporate Symposium
By Chong Kun Dang Pharmaceutical

Chairperson: TBD
Saturday 5 September

07:30-08:00

Qualified of new obesity drug through patient case Bo-Yeon KIM Division of Endocrinology and Metabolism, Soonchunhyang University, Korea


Corporate Symposium
By Handok

Chairperson: TBD
Saturday 5 September

07:30-08:00

The multiple benefits of SGLT-2i: Ideal option for Asian T2DM patients Sang Youl RHEE Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine


Corporate Symposium
By TBD

Chairperson: TBD
Saturday 5 September

07:30-08:00

The recent guideline based on glucose lowering drugs 씠쁺 꽌슱꽦紐⑤퀝썝 궡遺꾨퉬궡怨


Corporate Symposium
By Novo Nordisk

Chairperson: TBD
Saturday 5 September

12:30-13:00

Liraglutide: Key opportunities beyond weight reduction Changhee JUNG Department of Endocrinology and Metabolism, University of Ulsan, Korea


Corporate Symposium
By Eli Lilly and Company

Chairperson: TBD
Saturday 5 September

12:30-13:00

TBD Ted WU The Royal Prince Alfred Hospital, Australia


Corporate Symposium
By Johnson & Johnson

Chairperson: Jin-Jo KIM (Incheon St. Mary's Hospital, Catholic University, Korea)
Saturday 5 September

12:30-13:00

TBD Ali AMINIAN Cleveland Clinic, USA


Corporate Symposium
By Takeda Pharmaceutical

Chairperson: TBD
Saturday 5 September

12:30-13:00

The power of one pill, NesinaAct for T2DM patients with atherosclerosis Jae hyuk LEE Department of Endocrinology and Metabolism, Myongji Hospital, Korea